Skip to content

Progress in Neuro-Psychopharmacology and Biological Psychiatry

ISSN 1878-4216, 0278-5846

154 papers in the library · 1,492 citations · publishing 1985-2026

Papers

Sort Most recent Most cited

Serotonergic psychedelics as potential therapeutics for post-COVID-19 syndrome (or Long COVID): A comprehensive review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry March 20, 2025 Zhen Xuen Brandon Low, Shin Jie Yong, Hayam A Alrasheed et al.

In our ongoing battle against the coronavirus 2019 (COVID-19) pandemic, a major challenge is the enduring symptoms that continue after acute infection. Also known as Long COVID, post-COVID-19 syndrome (PCS) often comes with debilitating symptoms like fatigue, disordered sleep, olfactory dysfunction, and cognitive issues ("brain fog"). Currently, there are no approved treatments for PCS. Recent...

Persistent behavioural consequences of chronic adolescent cannabidiol (CBD) in a mouse model with increased susceptibility to Δ9-tetrahydrocannabinol and schizophrenia.

Progress in Neuro-Psychopharmacology and Biological Psychiatry March 1, 2025 Gabriela Visini, Rose Chesworth, Tim Karl

Increasingly, the cannabis sativa plant compound cannabidiol (CBD) is used to treat various psychiatric and neurological health conditions which occur in early life or adolescence, including schizophrenia and autism spectrum disorder. However, behavioural effects CBD during adolescence have received limited attention, and the long-lasting behavioural consequences of adolescent CBD treatment are...

Psychedelics in neuroinflammation: Mechanisms and therapeutic potential

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 31, 2025 Júnia L. de Deus, Juliana Marino Maia, Renato Nery Soriano et al. 27 citations

Neuroinflammation is a critical factor in the pathogenesis of various neurodegenerative and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and major depressive disorder. Psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT), have demonstrated promising therapeutic effects on neuroinflammation, primarily through interactions...

Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Stefania Chiappini, Amira Guirguis, Nicolò Schifano et al. 12 citations

Intranasal esketamine, approved with oral antidepressants for adults with treatment-resistant depression (TRD), is the S-enantiomer of ketamine and has higher potency and affinity for N-Methyl-d-Aspartate receptors. Administered intranasally, it offers rapid absorption and onset, essential for severe depressive symptoms or suicidal impulses. Comparative studies on esketamine and ketamine's...

DOI: 10.1016/j.pnpbp.2024.111213 (opens in new tab) Full text (opens in new tab) S-ketamine Pharmacovigilance Urological safety Drug surveillance +5

Efficacy of single and repeated ketamine administration for suicidal ideation in adults with psychiatric disorders: A meta-analysis.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Wanting Feng, Chengfeng Chen, Yexian Zeng et al. 9 citations

Previous studies have demonstrated rapid-onset anti-suicidal ideation effects of ketamine. This study aimed to compare the efficacy and duration of anti-suicidal thoughts following single- and repeated-dose ketamine administration. We retrieved published studies on ketamine for suicidal ideation (SI) from PubMed, OVID (MEDLINE), Web of Science, and Embase, spanning from inception to May 1,...

DOI: 10.1016/j.pnpbp.2024.111152 (opens in new tab) Full text (opens in new tab) Meta-analysis Suicidal ideation Ketamine therapy Suicide prevention +2

Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022).

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Emma I Kopra, Jenni Penttinen, James J Rucker et al. 9 citations

Psychedelic drugs are increasingly visible in society once more, but their risks and adverse effects have received less attention than perhaps they should. While fatalities associated with psychedelics appear rare, a systematic approach to characterising their aetiology is required to inform harm minimisation efforts. This study aimed to analyse prevalence and characteristics of...

DOI: 10.1016/j.pnpbp.2024.111177 (opens in new tab) Full text (opens in new tab) Psychedelics hallucinogens Entheogens Psychedelic drugs Pharmaceutical safety +7

Comparing psilocybin to metformin as neuroprotective agents against Parkinson's dementia: A systematic review of evidence and efficacy.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Randall D Ordovich-Clarkson, Maurice Jabbour, Daniel Arteaga Pelayo et al. 7 citations

Treatment of Parkinson's disease (PD) has remained largely unchanged and focuses primarily on symptomatic relief through activation of dopaminergic pathways. Currently, there are no proven prophylactic approaches to the prevention of PD. This systematic review seeks to compare two separate compounds, metformin (MTF) and psilocybin, as potential prophylactic therapeutics against the development...

DOI: 10.1016/j.pnpbp.2024.111155 (opens in new tab) Full text (opens in new tab) Psilocybin Neurodegenerative disorders neurodegeneration Brain disease Neural degeneration +9

Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Juliana Lima Constantino, Jens H van Dalfsen, Sara Massetti et al. 6 citations

Psilocybin represents a novel therapeutic approach for individuals with major depressive disorder (MDD) who do not respond to conventional antidepressant treatment. Investigating the influence of psilocybin on the pathophysiological processes involved in MDD could enhance our neurobiological understanding of the presumed antidepressant action mechanism. This systematic review aims to summarize...

Arketamine alleviates cognitive impairments and demyelination in mice with postoperative cognitive dysfunction via TGF-β1 activation.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Ting-Ting Zhu, Ming-Ming Zhao, Dan Xu et al. 5 citations

Postoperative cognitive dysfunction (POCD) is characterized by a decline in cognitive functions, including memory, attention, and executive abilities, following surgery, with no effective therapeutic drugs currently available. Arketamine, the (R)-enantiomer of ketamine, has shown promise in mitigating cognitive deficits in animal models. In this study, we investigated whether arketamine could...

DOI: 10.1016/j.pnpbp.2024.111228 (opens in new tab) Full text (opens in new tab) Arketamine Demyelination Postoperative cognitive dysfunction Surgery +5

Effects of 3,4-methylenedioxymethamphetamine on the gut microbiota and metabolites in the small intestine, cecum, and colon of male rats.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Dan Xu, Akifumi Eguchi, Rumi Murayama et al. 4 citations

3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy) is a widely abused recreational drug that has also gained interest for potential clinical applications in mental health. With the growing recognition of gut microbiota's role in mental health, this study examined whether repeated oral MDMA administration could affect gut microbiota in the small intestine, cecum, and colon of male rats. Repeated...

DOI: 10.1016/j.pnpbp.2024.111223 (opens in new tab) Full text (opens in new tab) Molly Entactogen Gastrointestinal tract Gut microbiota +6

The immune regulatory mechanism of ketamine-induced psychiatric disorders: A new perspective on drug-induced psychiatric symptoms.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Peipei Wang, Junmei Hu, Congliang Chen et al. 2 citations

Ketamine, a psychoactive substance strictly regulated by international drug conventions, is classified as a "new type drug" due to its excitatory, hallucinogenic, or inhibitory effects. The etiology of ketamine-induced psychiatric symptoms is multifaceted, with the immune regulatory mechanism being the most prominent among several explanatory theories. In recent years, the interaction between...

DOI: 10.1016/j.pnpbp.2024.111194 (opens in new tab) Full text (opens in new tab) New drugs Ketamine therapy Neuroimmunology research Psychiatric treatment +2

Processing of self-related thoughts in experienced users of classic psychedelics: A source localisation EEG study.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Anastasia Ruban, Mikołaj Magnuski, Justyna Hobot et al. 1 citation

Psychedelics have gained increasing interest in scientific research due to their ability to induce profound alterations in perception, emotional processing and self-consciousness. However, the research regarding the functioning of individuals who use psychedelics in naturalistic contexts remains limited. Here we aim to explore psychological and neurophysiological differences between...

DOI: 10.1016/j.pnpbp.2024.111196 (opens in new tab) Full text (opens in new tab) Electroencephalography Psychedelics Self-consiousness Self-related thoughts

Abnormal developmental of hippocampal subfields and amygdalar subnuclei volumes in young adults with heavy cannabis use: A three-year longitudinal study.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Xueyi Zhang, Zhengju Chen, Benjamin Becker et al.

Differences in the volumes of the hippocampus and amygdala have consistently been observed between young adults with heavy cannabis use relative to their non-using counterparts. However, it remains unclear whether the subfields of these functionally and structurally heterogenous regions exhibit similar patterns of change in young adults with long-term heavy cannabis use disorder (CUD). This...

Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry 2025 Zitong Wang, Brett Robbins, Ryan Zhuang et al. 15 citations

Chronic stress exerts profound effects on mental health, contributing to disorders such as depression, anxiety, and cognitive impairment. This study examines the potential of psilocybin to alleviate behavioral despair and cognitive deficits in a rodent model of chronic stress, focusing on the interplay between the Hypothalamic-Pituitary-Adrenal (HPA) axis and the Endocannabinoid System (ECS)....

DOI: 10.1016/j.pnpbp.2024.111243 (opens in new tab) Psilocybin magic mushrooms Psychedelics Hallucinogens Stress hormones +4

Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review

Progress in Neuro-Psychopharmacology and Biological Psychiatry 2025 Ines Erkizia-Santamaría, Igor Horrillo, J. Javier Meana et al. 10 citations

In the rapidly growing field of psychedelic research, psilocybin (and active metabolite psilocin) has been proposed as a promising candidate in the search for novel treatments for neuropsychiatric disorders. Clinical trials have revealed that psilocybin has a large, rapid, and persistent effect in the improvement of symptoms of depression and anxiety. The safety profile is considered...

DOI: 10.1016/j.pnpbp.2025.111249 (opens in new tab) Psilocybin Antidepressant Psychotherapist Narrative

Classic psychedelics and the treatment for alcoholism.

Progress in Neuro-Psychopharmacology and Biological Psychiatry December 20, 2024 Guilherme Lodetti, Rafael Mariano de Bitencourt, Eduardo Pacheco Rico 9 citations

Alcohol is a harmful drug, and reducing its consumption is a significant challenge for users. Furthermore, alcohol dependence is often treatment-resistant, and no completely effective treatment model is available for chemical dependence. Classic psychedelics, such as LSD, psilocybin, and ayahuasca have been used in different clinical and pre-clinical trials, demonstrating promising...

Cognitive changes in patients with unipolar TRD treated with IV ketamine: A systematic review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry December 20, 2024 Veronica Grasso, Gilmar Gutierrez, Najat Alzbeidi et al. 9 citations

Unipolar treatment-resistant depression (MDD-TRD) is associated with neurocognitive impairment. Ketamine, an emerging treatment for MDD-TRD, may have neurocognitive benefits, but evidence remains limited. We conducted a systematic search on EMBASE, Google Scholar, PsycINFO, and PubMed and included studies exploring the cognitive effects of intravenous (IV) ketamine treatment in the management...

DOI: 10.1016/j.pnpbp.2024.111095 (opens in new tab) Full text (opens in new tab) Major depressive disorder Intravenous ketamine Neurocognitive performance Treatment- resistant depression +5

The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies

Progress in Neuro-Psychopharmacology and Biological Psychiatry September 7, 2024 Zhen Xuen Brandon Low, Wei Shen Ng, Bey Hing Goh et al. 19 citations

Emerging evidence suggests that classical psychedelics possess immunomodulatory and anti-inflammatory properties; however, these effects are yet to be well-established. This systematic review aims to provide a timely and comprehensive overview of the immunomodulatory effects of classical psychedelics in preclinical studies. A systematic search was conducted on six databases, including CINAHL,...

Therapeutic modulation of the kynurenine pathway in severe mental illness and comorbidities: A potential role for serotonergic psychedelics.

Progress in Neuro-Psychopharmacology and Biological Psychiatry August 30, 2024 Antonella Campanale, Antonio Inserra, Stefano Comai 18 citations

Mounting evidence points towards a crucial role of the kynurenine pathway (KP) in the altered gut-brain axis (GBA) balance in severe mental illness (SMI, namely depression, bipolar disorder, and schizophrenia) and cardiometabolic comorbidities. Preliminary evidence shows that serotonergic psychedelics and their analogues may hold therapeutic potential in addressing the altered KP in the...

DOI: 10.1016/j.pnpbp.2024.111058 (opens in new tab) Full text (opens in new tab) Gut-brain axis Kynurenine pathway Serotonergic psychedelics Severe mental illness

Altered structural node of default mode network mediated general cognitive ability in young adults with obesity.

Progress in Neuro-Psychopharmacology and Biological Psychiatry August 1, 2024 Shengjie Xu, Kezhen Lv, Yuqi Sun et al.

BACKGROUND Obesity, characterized by excessive adiposity, is associated with brain structural abnormalities. Nevertheless, the relationships between altered structural node of default mode network (DMN), body mass index (BMI), general cognitive ability remained unclear in young adults. METHODS In this study, we divided a large sample of young adults into three BMI-based groups. We then...

Antidepressant effects of esketamine via the BDNF/AKT/mTOR pathway in mice with postpartum depression and their offspring.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 8, 2024 Han Qin, Miao Yu, Nianjiao Han et al. 27 citations

Postpartum depression (PPD) is a serious mental health problem that can negatively affect future generations. BDNF/AKT/mTOR signaling in the frontal lobe and hippocampus in mice is associated with depression, but its role in mice with PPD and their offspring is unknown. This study was aimed at investigating the effects of esketamine (ESK), a drug approved for treatment of refractory depression,...

DOI: 10.1016/j.pnpbp.2024.110992 (opens in new tab) Full text (opens in new tab) Bdnf/akt/mtor Postpartum depression ppd Postnatal depression Esketamine spravato +3

Time-dependent antidepressant-like effects of reelin and ketamine in the repeated-corticosterone model of chronic stress.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 8, 2024 Kaylene K A Scheil, Carla L Sánchez-Lafuente, Brady S Reive et al. 5 citations

There is an urgent need for novel antidepressants, given that approximately 30% of those diagnosed with depression do not respond adequately to first-line treatment. Additionally, monoaminergic-based antidepressants have a substantial therapeutic time-lag, often taking months to reach full therapeutic effect. Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist is the only current...

DOI: 10.1016/j.pnpbp.2024.110998 (opens in new tab) Full text (opens in new tab) Ketamine Chronic stress Corticosterone Rapid-acting antidepressants +5

Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 8, 2024 Jenny L Wiley, Julie A. Marusich, Bruce E. Blough et al.

The cannabis plant contains several cannabinoids, and many terpenoids that give cannabis its distinctive flavoring and aroma. Δ9-Tetrahydrocannabinol (Δ9-THC) is the plant's primary psychoactive constituent. Given the abuse liability of Δ9-THC, assessment of the psychoactive effects of minor cannabinoids and other plant constituents is important, especially for compounds that may be used...

Therapeutic potential of psychedelics: History, advancements, and unexplored frontiers.

Progress in Neuro-Psychopharmacology and Biological Psychiatry April 20, 2024 Juliana Marino Maia, Bruna Stefane Alves De Oliveira, Luiz G.s. Branco et al. 11 citations

Psychedelics (serotonergic hallucinogens) are psychoactive substances that can alter perception and mood, and affect cognitive functions. These substances activate 5-HT2A receptors and may exert therapeutic effects. Some of the disorders for which psychedelic-assisted therapy have been studied include depression, addiction, anxiety and post-traumatic stress disorder. Despite the increasing...

DOI: 10.1016/j.pnpbp.2024.110951 (opens in new tab) Full text (opens in new tab) Hallucinogens Neural interconnections Reward system Serotonin receptors

Use of nitrous oxide in the treatment of major depressive disorder and treatment-resistant major depressive disorder: A systematic review and meta-analysis nitrous oxide in depressive disorders.

Progress in Neuro-Psychopharmacology and Biological Psychiatry February 8, 2024 Peterson Rech, Rodrigo Miranda Custodio, Maria Laura Rodrigues Uggioni et al.

Major Depressive Disorder (MDD) has, as a conventional treatment, pharmacological therapy with selective monoamine reuptake inhibitors. However, the medication does not always have a rapid action for exacerbated cases, and moreover, it is estimated that 15 to 30% of patients do not respond effectively to conventional treatment, leading to 'treatment-resistant depressive mood disorder' (TRD)....

DOI: 10.1016/j.pnpbp.2023.110869 (opens in new tab) Full text (opens in new tab) Antidepressive agents Depressive disorder, major Depressive disorder, treatment-resistant Meta-analysis +1